By Andrew Morse
ZURICH--Novartis AG on Thursday reported a huge rise in
first-quarter profit as the proceeds of a series of transactions
that overhauled the Swiss drug giant flattered its results.
Basel-based Novartis said net profit attributable to
shareholders rose more than four times to $13 billion in the
quarter ended March 31 as the company recorded one-time gains of
$12.8 billion on the sales of businesses to GlaxoSmithKline PLC and
Eli Lilly and Co. Novartis reported $2.94 billion in net profit a
year earlier.
Core net income from continuing operations, a measure that
strips out exceptional items, fell 4% to $3.2 billion, from $3.33
billion a year earlier. Core net income would have risen 8% if
measured in constant currency, which strips out the impact of
foreign-exchange swings.
Sales dropped 7% drop to $11.94 billion in the quarter from
$12.77 billion a year earlier based on operations the company still
owns.
The figures come as Novartis begins to benefit from a series of
transactions valued at roughly $25 billion that refocused the drug
group on three core areas: pharmaceuticals, generics and eye care.
The sweeping overhaul, which included the purchase of
GlaxoSmithKline's oncology unit, has transformed Novartis into a
cancer powerhouse with roughly a fifth of its revenue expected to
come from cancer drugs.
Novartis also formed a joint venture with GSK to create an
over-the-counter business and sold the U.K. company most of its
vaccines business. Novartis also sold Lilly an animal health
business.
In a conference call to discuss the earnings, Chief Executive
Joe Jimenez said the transformation was helping the company boost
its profit margins--Novartis reported a 1.7 percentage point margin
expansion in the quarter--as it squeezed out costs, particularly in
procuring materials. The company said it saved $650 million in the
first quarter, $350 million of which came from buying in bulk.
Investors welcomed the results, with Novartis shares rising 1.4%
to 101.60 Swiss francs in late-morning trading.
Novartis said it expected net sales to grow in the mid-single
digits for the full year, with core operating income rising at a
faster high-single-digit pace.
Like other multinationals, Novartis is feeling the impact of
volatile currency markets, particularly a strong dollar that has
risen against other currencies. The company, which reports in the
U.S. dollars, said its revenue could be reduced by 10 percentage
points if early April exchange rates continue for the rest of the
year.
Mr. Jimenez said the company expected a decision from the U.S.
Food and Drug Administration in the third quarter on its LCZ696
heart medication. Many analysts see LCZ696 as a potential
blockbuster that could have sales of as much as $5 billion by
2020.
Write to Andrew Morse at andrew.morse@wsj.com
Access Investor Kit for Novartis AG
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=CH0012005267
Access Investor Kit for GlaxoSmithKline Plc
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=GB0009252882
Access Investor Kit for GlaxoSmithKline Plc
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US37733W1053
Access Investor Kit for Eli Lilly & Co.
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US5324571083
Access Investor Kit for Novartis AG
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US66987V1098
Subscribe to WSJ: http://online.wsj.com?mod=djnwires